caa a22 4500 39759089X CHVBK 20180308164938.0 cr unu---uuuuu 161202e199605 xx s 000 0 eng 10.1093/jac/37.suppl_A.105 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_A.105 Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis [Elektronische Daten] [P. Gehanno, P. Berche] In a double-blind, multicentre trial, 382 patients with a diagnosis of acute purulent sinusitis were randomised to receive sparfloxacin 200 mg once daily for 5 days following a loading dose of 400 mg on day 1 (n = 193) or cefuroxime axetil 250 mg twice daily for 8 days (n = 189). Patients were classified as success or failure according to clinical symptoms plus bacteriological and radiological data at the end of treatment and at a follow-up visit. In analyses of the intent-to-treat (n = 374) and evaluable populations (n = 304), the 5 day course of sparfloxacin was at least as effective and well tolerated as the 8 day course of cefuroxime axetil. The success rates at the end of treatment in the evaluable population were 82.6% and 83.2% in the sparfloxacin and cefuroxime axetil groups, respectively. The pathogens isolated most frequently were Haemophilus influenzae (33%) and Streptococcus pneumoniae (28%). Response rates according to the bacterial aetiology of the acute sinusitis were similar in the two treatment groups. Both drugs were well tolerated. The commonest adverse events were gastrointestinal and were reported in 2.6% and 3.8% of sparfloxacin-and cefuroxime axetil-treated patients, respectively. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Gehanno P. Service d'Oto-rhino-laryngologie, Hôpital Bichat-Claude Bernard Paris aut Berche P. Hôpital Necker-Enfants malades, Laboratoire de microbiologie Paris, France aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 105-114 0305-7453 37<105 1996 37 jac https://doi.org/10.1093/jac/37.suppl_A.105 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_A.105 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gehanno P. Service d'Oto-rhino-laryngologie, Hôpital Bichat-Claude Bernard Paris aut NATIONALLICENCE 700 1- Berche P. Hôpital Necker-Enfants malades, Laboratoire de microbiologie Paris, France aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 105-114 0305-7453 37<105 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford